Severe cutaneous adverse reactions (SCARs) are rare but potentially life-threatening. Children and adolescents are especially vulnerable due to developmental pharmacology, immature immune systems, and limited premarketing safety data. However, large-scale evidence of drug-specific SCAR patterns in pediatric populations remains limited.

Medication adherence is essential for the effective management of chronic diseases; however, adherence among patients remains suboptimal in China. Understanding the multidimensional determinants of adherence is critical in designing interventions to improve treatment outcomes. The health ecology model (HEM) provides a comprehensive framework that integrates individual, behavioral, social, and environmental influences on health behaviors.

Transitions of care (ToC) services are essential for maintaining care continuity. The complex and fast-paced nature of care and high patient turnover in emergency departments (EDs) create unique challenges and opportunities for improving transitional care. Although the benefits of pharmacy-supported ToC interventions are established in non-ED settings, there is a lack of evidence exploring their characteristics and outcomes in EDs.

IL-23p19 antagonists, selectively blocking IL-23 signaling via p19 targeting without affecting IL-12, represent a novel therapeutic class for inflammatory bowel disease (IBD). While multiple randomized controlled trials (RCTs) have evaluated their efficacy and safety in IBD, findings remain fragmented and exhibit significant heterogeneity.

Pneumonia is a leading cause of morbidity and mortality worldwide, with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) representing the two most common subtypes. Antimicrobials are central to treatment; however, systematic reviews (SRs) evaluating their use have reported highly variable outcomes, limiting evidence synthesis and comparability. The development of a core outcome set (COS) may address this gap.

Inhaled therapies are essential for managing asthma and chronic obstructive pulmonary disease (COPD), but device choice carries environmental consequences. Inhaler devices influence climate impact; propellant-based metered-dose inhalers (MDIs) have substantially higher carbon footprints than non-propellant inhalers (NPIs). Ireland has committed to net-zero greenhouse gas emissions by 2050, making prescribing practices a relevant focus for mitigation.

Cladribine has been widely recognized as a therapeutic option for relapsing-remitting multiple sclerosis (MS), but there is still a dearth of real-world data regarding its safety profile.

The development of anti-drug antibodies against tumor necrosis factor inhibitors, such as infliximab and adalimumab, is a major cause of therapeutic failure in patients with immune-mediated inflammatory diseases (IMIDs). However, immunogenicity responses are heterogeneous, and drug exposure can be restored in selected cases through individualized management.

Cisplatin is a cornerstone chemotherapeutic agent frequently associated with dose-limiting ototoxicity. Increasing evidence suggests that immune-mediated mechanisms may influence interindividual susceptibility to this adverse effect; however, the role of inherited immune traits remains poorly understood.

Atrial fibrillation (AF) is a common cardiac arrhythmia with limited options for upstream prevention. While several anti-diabetic drugs have shown cardiovascular benefits, their potential role in modifying AF risk remains unclear.

Given that medication is often utilised to treat mental health conditions, pharmacists across sectors are well placed to provide enhanced care to patients beyond their knowledge of medicines. However, this requires pharmacists to be appropriately educated about mental health. This study explores the priorities of pharmacy students for learning about mental health.

Awareness of planetary health has grown across healthcare professions, and the pharmacy sector, responsible for the lifecycle of medicines from production to disposal, plays a significant role in both perpetuating and mitigating environmental harm. However, pharmacy education omits environmental sustainability as a structured component.

Anti-angiogenic therapy has demonstrated therapeutic potential for several malignancies; however, its clinical efficacy in gastric cancer (GC) remains limited. To better understand the evolution of this field, comprehensive bibliometric analysis is required to map research trends, identify key contributors, and highlight emerging hotspots.

Physician burnout, marked by emotional exhaustion, depersonalization, and diminished professional efficacy, poses a significant threat to healthcare quality and workforce sustainability. Clinical pharmacists are increasingly recognized for their potential to enhance patient outcomes, reduce costs, and alleviate physician workload. Despite growing interest in embedding pharmacists within primary care teams, limited research explores pharmacists' own perspectives on their role in mitigating burnout and the conditions that support successful integration.

The standard treatment for Hormone Receptor-Positive breast cancer (BC) is Oral Endocrine Therapy (OET). OET reduces BC recurrence rates by ~ 50%, and non-adherence to OET leads to worse outcomes. However, OET adherence remains suboptimal, particularly among low socioeconomic status populations.

Daily intravenous dosing of cefepime, meropenem and ceftazidime/avibactam is recommended in patients receiving intermittent hemodialysis (IHD), but requires hospitalization or frequent clinic visits. High dose post-HD administration may offer a more convenient outpatient alternative, but supporting data is limited.

Depression affects approximately 5% of the global adult population, and its clinical and economic burden is particularly pronounced among individuals with chronic conditions such as diabetes mellitus, where it is frequently underdiagnosed and inadequately managed. Pharmacists play an important role in managing chronic diseases, including depression, through screening and medication management.